Congruence Therapeutics
Congruence Therapeutics is a drug discovery company operating in the United States and Canada, utilizing advanced technologies like protein dynamics, biophysics, machine learning, and computational chemistry to develop small molecule stabilizers.
Company Overview
Congruence Therapeutics is a drug discovery company operating in the United States and Canada. The company harnesses the power of protein dynamics, biophysics, machine learning, and computational chemistry to advance the field of drug discovery. With headquarters in Montreal, Quebec, Canada, and a U.S. location in Chapel Hill, North Carolina, Congruence Therapeutics aims to move beyond static drug discovery methods towards predictive models.
Drug Discovery Engine: Revenir™
The company's proprietary computational drug discovery engine, Revenir™, captures the biophysical changes caused by mutations in proteins, allowing the visualization of proteins in their full and dynamic state. Revenir™ enables the design of small molecule stabilizers by modeling protein dynamics and surface topology features. This innovative engine avoids the need for high throughput screening and rapidly identifies functional pockets and novel chemical matter, achieving unprecedented hit rates and reducing the time and cost of drug discovery.
Financing Rounds
Congruence Therapeutics announced the completion of a Series A financing extension in March 2023, led by BDC Capital’s Thrive Venture Fund. This extension brought the total amount raised to over US$65 million. The first part of the Series A financing was completed in December 2021, raising US$50 million. This funding supports the company's ongoing efforts to address significant unmet medical needs through their innovative drug discovery approaches.
Therapeutic Pipeline
The company's therapeutic pipeline focuses on designing small molecules for diseases with high unmet medical needs, including cancer, genetic obesity, α1-Antitrypsin deficiency, and GBA-driven Parkinson’s disease. Congruence Therapeutics emphasizes first-in-class and best-in-class potential treatments, leveraging their computational drug discovery engine to rapidly identify and develop promising therapeutic candidates.
Operations and Locations
Congruence Therapeutics conducts its operations from two main locations: its headquarters in Montreal, Quebec, Canada, and a U.S. location in Chapel Hill, North Carolina. These strategic locations support the company's goal of advancing drug discovery on an international scale and facilitating collaboration across borders.